A breakthrough technology enabling ENT surgeons to perform ear tube procedures in the comfort of the office without putting a child under general anesthesia.
Designed by Parents. Focused on Children.
Each year, close to 1 million children undergo ear tube procedures, called a tympanostomy, under general anesthesia in the United States.¹ As parents, including a pediatric anesthesiologist, the founders of Preceptis Medical understood the stress and costs associated with putting young children to sleep for surgery. Preceptis’ FDA Cleared Hummingbird Device provides a new option for ENTs and parents to choose the best option for their children.²
The Hummingbird is a FDA 510k cleared device that places an ear tube into the child’s eardrum in a single pass, significantly reducing trauma and improving usability for the ENT surgeon.
The Hummingbird device is currently being used in clinical studies at leading pediatric institutions around the country.
A pediatric anesthesiologist and two medical device engineers came together to create a solution for something personal. The team has worked together for over 10 years to get it right.
Ear Tubes. Safer. Simplified.
Hear From Our Hummingbird Parents.
“We got hummingbird tubes for my son and it was a no brainer to do the same when my daughter needed tubes. We would do it again for our third child.”
“Our son recovered immediately. And he was awesome for the rest of the day. The procedure was easy on my child and easy on me as a parent.”
“No need for general anesthesia and arguably more important, no need to ask our toddler to fast before the procedure was completed! It was also much less expensive than traditional ear tubes.”
“Couldn’t have been more amazed at how quick this procedure was. This has been a true life saver.”
Connect With Hummingbird!
10900 89th Avenue North, Suite #4 Maple Grove, MN 55369
Indications For Use: The Hummingbird® Tympanostomy Tube System (HTTS) is intended to deliver a tympanostomy tube (also referred to as a ventilation tube) through the tympanic membrane of the patient and is indicated to be used in office settings for children 6-24 months old.
¹ Source: IBM Marketscan Commercial Claims and Medicaid Database
² Source: K200952 510(k) Summary